How many times must it be discussed?
1. Dr. Liau states that most or all long lived patients have not evented.
2. That initially means little to no crossovers from placebo in that group.
3. Dr. Liau states it is important to get DCVax-l early in order to increase chance of long term survival.
4. Crossovers from placebo, whether misdiagnosed as psPD or correctly diagnosed as progressed, do not get DcVax-l early. They get it later than the treatment group, sometimes much later.
5. Idh-1 mutant tend toward pseudoprogression with SOC and live longer than real GBM (SOC) regardless of treatment beyond SOC, but these patients are no longer considered GBM, so no impact on trial if misdiagnosed as progressed.
6. DCVax-l does not tend to move the needle on IDH-1 mutant, so serendipitously benefits from global change in GBM definition.
Market Data 
Markets 
AI
